Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.37 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.33 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20834806 | 0.87 | POLRMT (0.59) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL20960149 | 0.86 | POLRMT (0.58) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL21120428 | 0.84 | POLRMT (0.56) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL27438391 | 0.84 | POLRMT (0.39) | POLRMT | |
| SCHEMBL24942272 | 0.83 | POLRMT (0.67) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL19412771 | 0.80 | POLRMT (0.61) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL23827914 | 0.79 | POLRMT (0.70) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL19779239 | 0.78 | POLRMT (0.58) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL17106862 | 0.78 | POLRMT (0.58) | POLRMTP2RY1P2RY2P2RY11P2RX1 | |
| SCHEMBL24942286 | 0.78 | POLRMT (0.62) | POLRMTP2RY1P2RY2P2RY11P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210395288-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | JANSSSEN BIOPHARMA, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| WO-2019053696-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | POLRMT 48/4885P2RY1 162/4885P2RY2 605/4885 |
| US-20210395288-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | POLRMT 79/4885P2RY1 286/4885P2RY2 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.